Efficacy of Topical Apraclonidine for the Treatment of Ocular Synkinesis

• Status: Not yet recruiting
• Trial end date: 2024-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine efficacy of apraclonidine for patients with ocular synkinesis, who are seen in the UAB Facial Nerve Clinic.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Alabama at Birmingham
• Treatments: Apraclonidine

Criteria

Inclusion Criteria:

• Age 18 years or older

• Ability to speak and comprehend English

• Ability to consent for themselves

• Diagnosis of synkinesis affecting eye movement

Exclusion Criteria:

• Age less than 18 years

• Unable to speak and comprehend English

• Unable to consent for themselves

• Diagnosis of congenital ptosis, Horner syndrome, myasthenia travis, mechanical ptosis

• Visual field loss from causes unrelated to facial nerve injury

• Currently receiving monoamine oxidase inhibitors

• Known hypersensitivity to apraclonidine or other components of the drug under study